The orally available IDH1 inhibitor ivosidenib (IVO) demonstrated efficacy as a single agent in both ND and R/R-AML [11,41], and was evaluated in combination with VEN with or without AZA in a PIb/II study of IDH1-mutated myeloid malignancies [42]. Here, IDH1 is linked to myeloid neoplasm.